OTCMKTS:PIRS
Pieris Pharmaceuticals Stock News
$10.97
-0.280 (-2.49%)
At Close: May 17, 2024
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
11:54am, Friday, 23'rd Jun 2023
Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
04:30pm, Friday, 02'nd Jun 2023
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technol
Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites
12:55am, Wednesday, 17'th May 2023
Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate.
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
11:16am, Friday, 12'th May 2023
Penny stocks under $1 to watch before next week. The post Best Penny Stocks To Buy Now?
Best Penny Stocks to Buy? 3 Under $1 To Watch Before Next Week
01:23pm, Thursday, 11'th May 2023
Penny stocks under $1 to watch right now. The post Best Penny Stocks to Buy?
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Wednesday, 10'th May 2023
Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago.
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
04:30pm, Tuesday, 02'nd May 2023
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
03:40pm, Wednesday, 29'th Mar 2023
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Ste
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
09:59am, Wednesday, 29'th Mar 2023
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
08:00am, Wednesday, 23'rd Nov 2022
BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Call Transcript
12:23pm, Wednesday, 02'nd Nov 2022
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Thomas Bures - SVP & CFO Stephen Yoder - CEO, President & Director Shane O
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
08:00am, Wednesday, 26'th Oct 2022
BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
04:01pm, Thursday, 08'th Sep 2022
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript
05:14pm, Saturday, 06'th Aug 2022
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder - President and Chief Executi
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
01:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
